“The company’s aggressive growth target for 2017 will be anchored on how well we perform in our core products as well as in our joint commitment to pursue success for our new business portfolio composed of critical care products which were launched in 2016”, Uni-Pharma’s Board said in a statement.
The company’s core products involve injectable antibiotics and injectable anti-ulcerants which have defined the roadmap to its current standing in the market. In the middle of 2016, Uni-Pharma introduced its expansion products, Norepinephrine 4mg and 2mg ampoules and Nicardipine 10mg ampoules which have since been the center of focus in terms of hospital inclusion. So far the company has been successful in gaining entry of either or both products in the key and major hospitals in Metro Manila and adjoining provincial areas. Both medicines will be pivotal and instrumental in the achievement of the company’s growth target of 70% for this year.
No new product is targeted for launch this year as the thrust of management is to achieve organic growth for its existing core medicines and at the same time focus on the inclusion of the newly-introduced critical care portfolio in hospitals and making sure that both products perform significantly where they are already available.